In this work we studied the effects on MM cell‐lines of two classes of bromodomain (BET and CBP/Ep300) inhibitors, with putatively distinct transcriptional effects, with the aim to disrupt the oncogenic feedback loop between MYC and IRF4. This evidence concerns the gene IRF4 and Miyoshi myopathy.